NeurologyLive® Staff

Neurology News Network for the week ending January 8, 2022. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 7, 2022.

Key takeaways from a larger discussion surrounding the utilization of novel oral agents as therapy for patients with relapsing-remitting multiple sclerosis.

The patient factors and other variables that impact first-line treatment decisions in relapsing-remitting multiple sclerosis.

The types of tests used to monitor response to novel oral therapies used in relapsing-remitting multiple sclerosis.

The latest CME course features a trio of experts that will help advanced practice providers provide optimal patient management and education in DBS treatment.

Here's what is coming soon to NeurologyLive®.

Neurology News Network for the week ending January 1, 2022. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 31, 2021.

Check out the top stories from the field of sleep medicine from our coverage in 2021, including new understandings of insomnia and daytime sleepiness.

Take a look back at some of the most-viewed, top video series with key experts in neurology and their in-depth discussions, part of NeurologyLive®'s Year in Review.

As part of NeurologyLive®'s Year in Review, take a look at some of the most engaging conversations the team has had with experts in neurology this past year.

We’ve compiled the top stories from 2021 across the breadth of the neuromuscular field, from clinical developments to conversations in management and beyond.

As part of NeurologyLive®'s Year in Review, take a look at some of the most listened to and engaging conversations from the Mind Moments™ podcast from this past year.

As part of NeurologyLive®'s Year in Review, take a look at some of the biggest FDA approvals and decisions from this past year.

These news stories were among the most-discussed conversations in the field and were often included in NeurologyLive®'s coverage in multiple sclerosis.

As part of NeurologyLive®'s Year in Review, take a look at some of the best features that have been published on the site this year.

Here's what is coming soon to NeurologyLive®.

Take a look back at some of the most top video interviews with key experts in neurology and their insights and perspectives on topics in neurology subspecialties, as part of NeurologyLive®'s Year in Review.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 24, 2021.

These news stories led the pack in conversations in the field of epilepsy and were often included in NeurologyLive®'s coverage of seizure disorders.

These news stories dominated the conversations in the field and were often included in NeurologyLive®'s coverage in Alzheimer disease and dementia.

Following previous discussions about novel oral therapies available as treatment for relapsing-remitting multiple sclerosis, a small panel of neurologists comment on factors that affect which agent they select.

Characteristics that make the purine antimetabolite, cladribine, a unique treatment option for relapsing-remitting multiple sclerosis.

Here's what is coming soon to NeurologyLive®.

Neurology News Network for the week ending December 18, 2021. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 17, 2021.

The advantages of using the pyrimidine synthesis inhibitor teriflunomide to treat relapsing-remitting multiple sclerosis.

Considerations that affect which S1P receptor modulator may be used to treat relapsing-remitting multiple sclerosis, and how to best utilize them during COVID-19.

Ellie Harrington, lecturer in genetic counseling, provides answers for patients with ALS who might be unfamiliar with genetic testing and counseling.